No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
18 fdg |
- |
- |
- |
- |
1件: 145 |
2 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
3 |
Acth |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
5件: 13, 66, 145, 193, 222 |
4 |
Adrenocorticotropin |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 145 |
5 |
Adrenocorticotropin hormone |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 145 |
6 |
Cannabidiol |
Cannabidiol |
D10915 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
13件: 6, 13, 46, 95, 96, 97, 140, 144, 145, 157, 158, 193, 271 |
7 |
Cannabidiol oral solution |
Cannabidiol |
D10915 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
4件: 140, 144, 145, 193 |
8 |
Cosyntropin |
Tetracosactide |
D00284 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
3件: 83, 113, 145 |
9 |
Cosyntropin injectable suspension 1 mg/ml + vigabatrin |
Vigabatrin |
D00535 |
1件: ABAT |
7件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
1件: 145 |
10 |
Cosyntropin injectable suspension, 1 mg/ml |
Tetracosactide |
D00284 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 145 |
11 |
Decortin |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
5件: 46, 96, 97, 113, 145 |
12 |
Decortin h |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 145 |
13 |
Ganaxolone |
Ganaxolone |
D04300 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
3件: 145, 152, 206 |
14 |
Gwp42003-p |
- |
- |
- |
- |
5件: 140, 144, 145, 156, 158 |
15 |
Intravenous methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 145 |
16 |
Jbpos0101 |
- |
- |
- |
- |
1件: 145 |
17 |
M071754 |
- |
- |
- |
- |
1件: 145 |
18 |
Methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
36件: 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
19 |
Modified atkins diet |
- |
- |
- |
- |
2件: 145, 157 |
20 |
Null |
- |
- |
- |
- |
17件: 6, 13, 14, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271 |
21 |
Oral pednisolone |
- |
- |
- |
- |
1件: 145 |
22 |
Oral prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 49, 145 |
23 |
Prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
38件: 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
24 |
Pyridoxine |
Pyridoxine |
D02179, D08454 |
- |
- |
2件: 93, 145 |
25 |
Pyridoxine plus prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 145 |
26 |
Radiprodil |
Radiprodil |
- |
- |
- |
1件: 145 |
27 |
Sabril |
Vigabatrin |
D00535 |
1件: ABAT |
7件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
1件: 145 |
28 |
Sabril granules for oral use |
Vigabatrin |
D00535 |
1件: ABAT |
7件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
1件: 145 |
29 |
Sabril sachets |
Vigabatrin |
D00535 |
1件: ABAT |
7件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
1件: 145 |
30 |
Sabrilex |
- |
- |
- |
- |
1件: 145 |
31 |
Sabril® |
- |
- |
- |
- |
1件: 145 |
32 |
Soluble prednisolone tablets |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 145 |
33 |
Spt3162 |
- |
- |
- |
- |
1件: 145 |
34 |
Synacthen depot |
Tetracosactide |
D00284 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
2件: 83, 145 |
35 |
Tetracosactide |
Tetracosactide |
D00284 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
4件: 83, 113, 145, 222 |
36 |
Tetracosactide acetate |
Tetracosactide |
D00284 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
2件: 83, 145 |
37 |
Vgb-st |
- |
- |
- |
- |
1件: 145 |
38 |
Vgb-st soluble tablets |
- |
- |
- |
- |
1件: 145 |
39 |
Vigabatrin |
Vigabatrin |
D00535 |
1件: ABAT |
7件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
2件: 145, 158 |
40 |
Vigabatrin: vigabatrin new st formulation then sabril® |
Vigabatrin |
D00535 |
1件: ABAT |
7件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
1件: 145 |